Close Menu

NEW YORK – Agilent Technologies announced that it is withdrawing its second-quarter and fiscal year 2020 guidance due to the global impact of COVID-19 on its business activities.

While the firm's Q2 revenues rose 2 percent through March, it noted a significant disruption in business activity in late March, especially in the US and Europe, as customers closed or restricted access to their facilities in an attempt to slow the spread of the coronavirus.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.